GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FibroBiologics Inc (NAS:FBLG) » Definitions » EV-to-EBITDA

FibroBiologics (FibroBiologics) EV-to-EBITDA : -23.91 (As of May. 11, 2024)


View and export this data going back to 2024. Start your Free Trial

What is FibroBiologics EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, FibroBiologics's enterprise value is $278.88 Mil. FibroBiologics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-11.67 Mil. Therefore, FibroBiologics's EV-to-EBITDA for today is -23.91.

The historical rank and industry rank for FibroBiologics's EV-to-EBITDA or its related term are showing as below:

FBLG' s EV-to-EBITDA Range Over the Past 10 Years
Min: -137.91   Med: 0   Max: 2.17
Current: -23.91

During the past 3 years, the highest EV-to-EBITDA of FibroBiologics was 2.17. The lowest was -137.91. And the median was 0.00.

FBLG's EV-to-EBITDA is ranked worse than
100% of 460 companies
in the Biotechnology industry
Industry Median: 9.53 vs FBLG: -23.91

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-11), FibroBiologics's stock price is $9.29. FibroBiologics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.366. Therefore, FibroBiologics's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


FibroBiologics EV-to-EBITDA Historical Data

The historical data trend for FibroBiologics's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FibroBiologics EV-to-EBITDA Chart

FibroBiologics Annual Data
Trend Dec21 Dec22 Dec23
EV-to-EBITDA
- - -

FibroBiologics Quarterly Data
Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial - - - - -

Competitive Comparison of FibroBiologics's EV-to-EBITDA

For the Biotechnology subindustry, FibroBiologics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


FibroBiologics's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, FibroBiologics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where FibroBiologics's EV-to-EBITDA falls into.



FibroBiologics EV-to-EBITDA Calculation

FibroBiologics's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=278.876/-11.666
=-23.91

FibroBiologics's current Enterprise Value is $278.88 Mil.
FibroBiologics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-11.67 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


FibroBiologics  (NAS:FBLG) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

FibroBiologics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=9.29/-0.366
=At Loss

FibroBiologics's share price for today is $9.29.
FibroBiologics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.366.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


FibroBiologics EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of FibroBiologics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


FibroBiologics (FibroBiologics) Business Description

Comparable Companies
Traded in Other Exchanges
Address
455 E. Medical Center Boulevard, Suite 300, Houston, TX, USA, 77598
FibroBiologics Inc is an early-stage, cell therapy company. Its primary focus is the initiation and progression of preclinical studies and clinical-stage FDA trials related to fibroblast treatments for Degenerative Disc Disease, Multiple Sclerosis, Cancer, Wound Healing, and other diseases.

FibroBiologics (FibroBiologics) Headlines